Interactive Dashboard
The Data Explorer
For each question, responses are grouped into topics. Responses that touch on multiple ideas can fit into more than one topic. Words in [brackets] were manually edited to keep the interviewee or others they mentioned anonymous, and some filler text (like, um, etc.) was removed for clarity. Use the selections below to filter, and click any bar or bubble to read the quotes.
Section
Crosscutting Themes
Critiqued the Current Funding Ecosystem
Figure 1. How people critique the way climate biotech is funded, (N=63). Figure 1A: a stage or type of work that is hard to get funded (left panel). Figure 1B: venture capital being the wrong shape for the work (right panel). A person can appear in both panels.
Named the Economics of Scaling as a Central Concern
“That valley of death they often talk about in commercialization, it's really steep and really wide.”
raised in Q2 · What's been hard
“The cheaper, faster, dirtier way is always going to be more economical, at least in the short run.”
raised in Q3 · What holds the field back
“I'm not an expert in any way in doing TEAs. … We're a bunch of biologists.”
raised in Q11 · Not on the radar
Figure 2. Quotes of those who named the economics of scaling as a central concern, (N=63). One quote per person, each tagged with the interview question it was raised in.
Point to a Gap in Their Climate Biotech Community
Figure 3. The gap people point to in their climate biotech community, (N=63). Figure 3A: a collaboration missing from the field (left panel). Figure 3B: feeling geographically isolated or siloed (right panel). A person can appear in both panels.
Catch a mistake or don’t agree with our categorization?
Help us fix it.